A
Apogee Therapeutics
Develops advanced biologics for treating inflammatory and immune diseases like atopic dermatitis and asthma
About Apogee Therapeutics
Apogee Therapeutics is a biotechnology startup that specializes in developing unique biological treatments for diseases with high unmet needs, such as atopic dermatitis (a type of skin inflammation), chronic obstructive pulmonary disease (a type of lung disease), and other inflammatory and immune diseases. The company aims to improve the current standard of care for these diseases, believing that patients deserve the best possible treatment.
Read full description
Apogee's business model revolves around the creation and development of antibody therapeutics, which are drugs that can stimulate the body's immune system to fight diseases. These drugs target well-established biological drivers and development pathways, with a primary focus on improving treatments for atopic dermatitis and chronic obstructive pulmonary disease.
The company's revenue is likely generated through the sale of these therapeutics to healthcare providers and patients. It may also earn income from partnerships with other biotech firms or pharmaceutical companies, and potentially from grants or investments for research and development.
Apogee's team consists of experienced drug developers and operators who are motivated by the goal of providing better treatment options for people living with inflammatory and immune diseases. The company places a strong emphasis on creating a psychologically safe environment where everyone feels comfortable sharing ideas, reflecting its people-first philosophy.
At a glance
- Founded
- 2022
- Headquarters
- Waltham, United States
- Listing
- IPO 2023
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Fairmount Funds Management- VPVenrock Healthcare Capital Partners
Fidelity Investments
RTW Investments
RA Capital Management
Wellington Management
OrbiMed
Deep Track Capital- PFPerceptive Xontogeny Venture Fund
Series B and later4 investors entered at this stage
Paragon Therapeutics- PMPlatinum Investment Management
Great Point Partners
Blackstone
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
11 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apogee Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apogee Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.